CRP and COVID-19: Interleukin-6 (IL-6) is a pivotal cytokine in acute phase responses, and its inhibition may alleviate acute innate-immunity reactions and the related cytokine storm.59,60 IL-6 levels are correlated to the disease severity and the viral load in patients with COVID-19.61 They are also predicting the need for mechanical ventilation when combined with elevated levels of CRP.62 As it has been shown in other hyperferritinaemic inflammatory syndromes, the use of tocilizumab as a complementary therapy may be beneficial in severe cases of COVID-19.63,64